The present invention relates to methods for increasing embryo implantation rate in a uterus, for preventing embryo implantation failure in a female subject suffering PCOS and for improving pregnancy rate comprising administering a composition comprising myo-inositol and D-chiro-Inositol in a weight ratio between 1:1 to 9:1 respectively to a female subject suffering PCOS. The invention also relates to a composition comprising myo-inositol and D-chiro-Inositol in a weight ratio between 1:1 to 9:1 respectively for use in the treatment or prevention of PCOS in a female subject, for use in the treatment or prevention of infertility in a female subject suffering polycystic ovary syndrome, or for use in preventing or reducing the risk of ovarian hyperstimulation syndrome in a female subject suffering polycystic ovary syndrome and subjected to ovary stimulation treatment. The invention also relates to a soft capsule comprising a) a soft capsule shell and b) a pharmaceutical composition comprising myo-inositol and D-chiro-Inositol in a weight ratio between 1:1 to 9:1 respectively.

The present invention provides ingestible dosage form articles such as opaque capsules with reduced light transmittance.

The invention discloses opaque capsule shells made from gelatin with ground CaCO.sub.3 as opacifier; and a method for making them.

Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

The present invention relates to a salivary gland therapeutic agent using the effects of a cell-derived vesicle of enhancing the proliferation capacity of salivary gland cells, promoting an amylase activity, and enhancing transepithelial resistance. A pharmaceutical composition comprising the cell-derived vesicle according to the present invention has the effects of enhancing the proliferation capacity of salivary gland cells damaged by radiation, promoting amylase activity, increasing transepithelial resistance, enhancing the expression of Aquaporin 5, and increasing the amount of saliva secretion. Therefore, the pharmaceutical composition comprising the cell-derived vesicle of the present invention can be used for preventing and treating salivary gland diseases, and thus can be widely used in the pharmaceutical industry and health functional food field.

The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

The present invention relates to a liquid crystalline structure-forming omega-3-fatty acid composition and, more specifically, provides an omega-3-fatty acid composition comprising: amphoteric lipids which form liquid crystalline structures when exposed to aqueous media such as gastrointestinal juice; omega-3 fatty acids or derivatives thereof; and a liquid crystalline structure-forming aid. The omega-3-fatty acid composition forms self-assembled lyotropic liquid crystals which are thermodynamically stable in structure, irrespective of digestion in the gastrointestinal tract, thereby promoting the solubilization and absorption rate of omega-3-fatty acids as well as providing preparations 30% or more smaller in size than conventional soft gel capsules of omega-3-fatty acid preparations. Thus, the composition can be taken with more ease by geriatric patients and the like and allows for provision of omega-3-fatty acid preparations increasing in in-vivo dissolution and absorption.

This invention relates to a novel anti-RNA virus, including anti-SARS-CoV-2 virus, pharmaceutical composition Avifavir in tablets or capsules containing less than 50 wt % of micronized favipiravir, with the remainder being excipients.

Medicinal product Avifavir for the prevention and treatment of COVID-19 coronaviral disease, said medicinal product being a pharmaceutical composition in coated tablets containing 200 mg, 300 mg, 400 mg, or 600 mg of micronized favipiravir (less than 40-45%) with a particle size of less than 60 μm, with the remainder being excipients.

The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.